Literature DB >> 29420809

Unexpected Effects of Propiconazole, Tebuconazole, and Their Mixture on the Receptors CAR and PXR in Human Liver Cells.

Constanze Knebel1, Jannika Neeb1, Elisabeth Zahn2, Flavia Schmidt2, Alejandro Carazo3, Ondej Holas4, Petr Pavek3, Gerhard P Püschel5, Ulrich M Zanger6, Roderich Süssmuth7, Alfonso Lampen1, Philip Marx-Stoelting8, Albert Braeuning1.   

Abstract

Analyzing mixture toxicity requires an in-depth understanding of the mechanisms of action of its individual components. Substances with the same target organ, same toxic effect and same mode of action (MoA) are believed to cause additive effects, whereas substances with different MoAs are assumed to act independently. Here, we tested 2 triazole fungicides, propiconazole, and tebuconazole (Te), for individual and combined effects on liver toxicity-related endpoints. Both triazoles are proposed to belong to the same cumulative assessment group and are therefore thought to display similar and additive behavior. Our data show that Te is an antagonist of the constitutive androstane receptor (CAR) in rats and humans, while propiconazole is an agonist of this receptor. Both substances activate the pregnane X-receptor (PXR) and further induce mRNA expression of CYP3A4. CYP3A4 enzyme activity, however, is inhibited by propiconazole. For common targets of PXR and CAR, the activation of PXR by Te overrides CAR inhibition. In summary, propiconazole and Te affect different hepatotoxicity-relevant cellular targets and, depending on the individual endpoint analyzed, act via similar or dissimilar mechanisms. The use of molecular data based on research in human cell systems extends the picture to refine cumulative assessment group grouping and substantially contributes to the understanding of mixture effects of chemicals in biological systems.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29420809     DOI: 10.1093/toxsci/kfy026

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  7 in total

Review 1.  Candidate Proficiency Test Chemicals to Address Industrial Chemical Applicability Domains for in vitro Human Cytochrome P450 Enzyme Induction.

Authors:  Miriam Naomi Jacobs; Barbara Kubickova; Eugene Boshoff
Journal:  Front Toxicol       Date:  2022-06-20

2.  Impact of iron oxide nanoparticles on xenobiotic metabolism in HepaRG cells.

Authors:  Linn Voss; Kiymet Yilmaz; Lea Burkard; Janja Vidmar; Valerie Stock; Ute Hoffmann; Oliver Pötz; Helen Sophie Hammer; Matthias Peiser; Albert Braeuning; Katrin Löschner; Linda Böhmert; Holger Sieg
Journal:  Arch Toxicol       Date:  2020-09-10       Impact factor: 5.153

Review 3.  The Connection of Azole Fungicides with Xeno-Sensing Nuclear Receptors, Drug Metabolism and Hepatotoxicity.

Authors:  Philip Marx-Stoelting; Constanze Knebel; Albert Braeuning
Journal:  Cells       Date:  2020-05-11       Impact factor: 6.600

Review 4.  Metabolism-Disrupting Chemicals and the Constitutive Androstane Receptor CAR.

Authors:  Jenni Küblbeck; Jonna Niskanen; Paavo Honkakoski
Journal:  Cells       Date:  2020-10-15       Impact factor: 6.600

5.  Polycyclic Aromatic Hydrocarbons Activate the Aryl Hydrocarbon Receptor and the Constitutive Androstane Receptor to Regulate Xenobiotic Metabolism in Human Liver Cells.

Authors:  Lisa Goedtke; Heike Sprenger; Ute Hofmann; Felix F Schmidt; Helen S Hammer; Ulrich M Zanger; Oliver Poetz; Albrecht Seidel; Albert Braeuning; Stefanie Hessel-Pras
Journal:  Int J Mol Sci       Date:  2020-12-31       Impact factor: 5.923

6.  Okadaic acid influences xenobiotic metabolism in HepaRG cells.

Authors:  Leonie T D Wuerger; Helen S Hammer; Ute Hofmann; Felicia Kudiabor; Holger Sieg; Albert Braeuning
Journal:  EXCLI J       Date:  2022-08-01       Impact factor: 4.022

7.  Cross-species analysis of hepatic cytochrome P450 and transport protein expression.

Authors:  Helen Hammer; Felix Schmidt; Philip Marx-Stoelting; Oliver Pötz; Albert Braeuning
Journal:  Arch Toxicol       Date:  2020-11-04       Impact factor: 5.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.